This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

6 Stocks at New 52-Week Highs


Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Inhibitex (INHX) is focused on the development of differentiated anti-infective products to prevent or treat serious infections. This stock is trading up 18% to $10.53 in recent trading, after it hit a 52-week high of $11.98 earlier today.

Today's Range: $11.10-$11.98

52-week Range: $2.00-$11.98

Volume: 7,000,000

Three-Month Average Volume: 1,419,000

Inhibitex has a market cap of $896.45 million and an enterprise value of $646.86 million. Its estimated growth rate for this year is 5.4%, and for next year it's pegged at -5.7%. The current short interest as a percentage of the float for Inhibitex is 3.4%.

This stock is soaring higher today as traders jamp into any stock with exposure to hepatitis C treatments after Gilead Sciences struck a deal to buy Pharmasset for $11 billion. Inhibitex is currently developing hepatitis C medicines.

From a technical standpoint, this stock is gapping up and breaking out above some past overhead resistance at $10.60 today on high volume. If this stock can manage to close above $10.60 and near its daily high of $11.98, then traders should look for continued upside.

That said, if INHX closes below $10.60, then I would expect to see the gap higher today get filled in the near future back toward $8.50.

Inhibitex shows up on a recent list of 13 Biotech Stocks Bought and Sold by Hedge Funds.
2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
AETI $2.55 -1.90%
HSTM $19.17 0.58%
RAI $48.46 2.10%
AAPL $93.65 -0.66%
FB $101.93 0.92%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs